09:55 AM EST - ProMetic Life Sciences Inc. : Presented today new data at the 2016 European Association for the Study of the Liver (EASL)'s 51st Annual Meeting – The International Liver Congress (ILC) in Spain. The new data confirms that PBI-4050's anti-fibrotic effect demonstrated in the livers of different animal models has been successfully reproduced in human hepatic stellate cells during in vitro preclinical experiments designed to simulate fibrogenesis in the liver. PBI-4050 was found to down-regulate key pro-fibrotic biomarkers considered to be driving the fibrotic process in NASH. ProMetic Life Sciences Inc.
shares T.PLI are trading down $0.01 at $3.11.
